Positron Emission Tomography/Magnetic Resonance Imaging in Patients

Study summary

This clinical trial studies positron emission tomography (PET)/magnetic resonance imaging (MRI) in patients undergoing PET/computed tomography (CT). Diagnostic procedures, such as PET/MRI, may help doctors diagnose cancer or help doctors predict a patient's response to treatment

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedmagnetic resonance imaging with positron emission tomography scanning

The study team can explain what participation involves.

Who it may be forColon Cancer · Head and Neck Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 24, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Case Comprehensive Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Not applicable
Sponsor: Case Comprehensive Cancer Center
Interventions being studied: Device: magnetic resonance imaging with positron emission tomography scanning

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Only patients who are referred by their physician to have a clinical PET/CT will be eligible to participate in the study
we propose to obtain a second PET/MRI on 100 patients after their clinical PET/CT imaging that spans several disease categories and includes the following cancers: lung, colon, melanoma, head/neck and lymphoma
In addition to oncology patients, we anticipate imaging a subset of non-cancer patients who will also be imaged subsequent to their clinical PET/CT who will be referrals from neurology and cardiology
All subjects will be at least 18 years old, or if under 18, parents or guardians must give consent
Subjects must be stable and have experienced no adverse events from previous clinical PET/CT examination

Reasons someone may not be able to joinExclusion criteria

Subjects who do not meet the above inclusion criteria
Subjects unwilling or unable to sign the informed consent form
Subjects who are cognitively impaired and thus unable to give informed consent
Subjects unable to undergo MRI scanning due to exclusion via University Hospital Case Medical Center (UHCMC) MRI restrictions (e.g. implanted metallic or electronic devices, hip or other joint replacements, history of kidney disease, unacceptable creatinine or glomerular filtration rate \[GFR\], etc)
Patients who are pregnant

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer CenterCleveland, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 24, 2020. Always confirm current availability with the study team.

View original record ↗